Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
gptkb:Pfizer
|
| gptkbp:acquisitionYear |
2022
|
| gptkbp:CEO |
gptkb:Vlad_Coric
|
| gptkbp:country |
gptkb:United_States
|
| gptkbp:focusesOn |
neurology
rare diseases migraine treatments |
| gptkbp:founded |
2013
|
| gptkbp:founder |
gptkb:Vlad_Coric
|
| gptkbp:headquarters_location |
New Haven, Connecticut, United States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Biohaven Pharmaceuticals
|
| gptkbp:industry |
pharmaceuticals
|
| gptkbp:notableProduct |
gptkb:Troriluzole
gptkb:Nurtec_ODT |
| gptkbp:numberOfEmployees |
~500
|
| gptkbp:publiclyTraded |
yes
|
| gptkbp:researchArea |
CGRP receptor antagonists
glutamate modulation |
| gptkbp:stock_symbol_(pre-acquisition) |
gptkb:BHVN
|
| gptkbp:website |
https://www.biohaven.com/
|
| gptkbp:bfsParent |
gptkb:Bill_Meury
|
| gptkbp:bfsLayer |
6
|